Trisomy 21 enhances human fetal erythro-megakaryocytic development

Blood

Volumn 112, Issue 12, 2008, Pages 4503-4506

  Chou, Stella T ^a,b   Opalinska, Joanna B ^a   Yao, Yu ^a   Fernandes, Myriam A ^a   Kalota, Anna ^b   Brooks, John S J ^c   Choi, John K ^a   Gewirtz, Alan M ^b   Danet Desnoyers, Gwenn Ael ^b   Nemiroff, Richard L ^b   Weiss, Mitchell J ^a,b,d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PENNSYLVANIA HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; TRANSCRIPTION FACTOR GATA 1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHROMOSOME MUTATION; ERYTHROCYTE; ERYTHROID CELL; EXPERIMENTAL TRANSPLANTATION; HEMATOPOIESIS; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEM CELL EXPANSION; TRISOMY 21; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; DOWN SYNDROME; ERYTHROID PRECURSOR CELL; FEMALE; FETAL TISSUE TRANSPLANTATION; GENETICS; HEMATOPOIETIC SYSTEM; HUMAN; LIVER; LIVER TRANSPLANTATION; MOUSE MUTANT; MYELOID PROGENITOR CELL; PATHOLOGY; PHYSIOLOGY; PREGNANCY; PRENATAL DEVELOPMENT;

ANIMALS; CELL DIFFERENTIATION; DOWN SYNDROME; ERYTHROCYTES; ERYTHROID PRECURSOR CELLS; FEMALE; FETAL TISSUE TRANSPLANTATION; HEMATOPOIETIC SYSTEM; HUMANS; LIVER; LIVER TRANSPLANTATION; MEGAKARYOCYTES; MICE; MICE, SCID; MYELOID PROGENITOR CELLS; PREGNANCY;

EID: 58149396964     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-157859     Document Type: Article

References (18)

1. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000;110:512-524.
2. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemo-genesis in Down syndrome. Blood. 2004;103: 399-406.
3. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005;5:11-20.
4. Massey GV, Zipursky A, Chang MN, et al. Aprospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. 2006;107:4606-4613.
5. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblas-tic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
6. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981-986.
7. Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103:2480-2489.
8. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr. 2005;217:126-134.
9. Bourquin JP, Subramanian A, Langebrake C, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A. 2006;103:3339-3344.
10. Ito E, Kasai M, Hayashi Y, et al. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome. Br J Haematol. 1995; 90:607-614.
11. Crispino JD. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol. 2005;16:137-147.
12. Taub JW, Mundschau G, Ge Y, et al. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood. 2004;104: 1588-1589.
13. Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007;110:2128-2131.
14. Ishikawa F, Yasukawa M, Lyons B, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005;106:1565-1573.
15. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A. 2002;99:11872-11877.
16. Ghinassi B, Sanchez M, Martelli F, et al. The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor. Blood. 2007;109:1460-1471.
17. Stachura DL, Chou ST, Weiss MJ. Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. Blood. 2006; 107:87-97.
18. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37: 613-619.